The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation.

ABSTRACT:

Background

Sodium glucose cotransporter 2 (SGLT2) inhibitors improve clinical outcomes in several populations including type 2 diabetes (T2D), chronic renal insufficiency, and heart failure (HF). However, limited data exist on their effects on atrial fibrillation (AF).

Methods

We conducted a retrospective cohort study using the National Health Insurance Service database. A total of 4,771 patients with T2D and AF who were newly prescribed SGLT2 inhibitors or DPP4 inhibitors were selected and matched in a 1:2 ratio by propensity score with 37 confounding variables. We assessed the effect of SGLT2 inhibitors on the composite outcome of either HF hospitalization or death.

Results

Over a median follow-up of 31 months, patients on SGLT2 inhibitors were associated with a low

SUBMITTER: Cho Y 

PROVIDER: S-EPMC11805423 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature